Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro
about
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversalDevelopment of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrateA critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): implications for drug design.Genetics of multidrug resistance.Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice.Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.Improving cancer chemotherapy with modulators of ABC drug transporters.Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistanceOvercoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives.Multidrug resistance (mdr) genes in human cancer.Multidrug resistance: a novel class of membrane-associated transport proteins is identified.Functional expression of mouse Mdr1 in an outer membrane permeability mutant of Escherichia coli.Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.Can the assessment of ABCB1 gene expression predict its function in vitro?Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transportersIn vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A.Design and synthesis of Selenazole-containing peptides for cocrystallization with P-glycoprotein.Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.The intriguing link between modulation of both multidrug resistance and ligand-toxin conjugate cytotoxicity.Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell lineEffects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitroMultidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for cyclosporine.The role of MDR-1 in refractory lymphoma.Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells.Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporinsThe polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.Development of cyclosporin A mediated immunity in L1210 leukaemia.Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin-resistant sublines.Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells.Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
P2860
Q21246014-6AA0960C-D12E-4985-B254-3BA8C03C0438Q28535627-AFC7D279-AB33-4EF7-B39D-F2F2D7D2652AQ33735167-757201A7-DBBD-41BC-BBCA-0D4436F07AAFQ34355578-A3A4A572-F41D-4677-833C-BF6E0D242837Q35587246-10793874-6A2C-40C2-AD20-8A50A3931963Q35904665-AC3D9542-9FB8-4CD4-8114-46CD429F38B1Q35994294-DF46E976-813E-4A4D-8AAF-5AA5B2266D0CQ36108251-4D1C0DC1-2F7A-49BC-BC7C-74B22D5F5AD5Q36254793-D7E14DFC-79E7-4F57-B4D3-37BDD30A9C81Q36467823-D0032F13-CDB8-4C04-90F6-C2943412C888Q36495579-2BE0D43E-F4C1-429F-8380-E4CA87721D98Q36527076-0954F16B-9B6B-4550-B009-9CCDDAD14899Q37565994-07404284-7262-411E-B67C-2B5D3E3E2349Q38818023-B24FBCBE-D065-4E74-906C-932A172A4E0EQ38947143-088FB86F-B522-4DD4-8AFD-4B487658C0F3Q39122325-4533B6DA-D7C4-4A4C-8B6A-CF6AD56C2A7DQ39204093-633784C5-71E3-4807-A070-D2E84C65D2B8Q39572897-21E972D1-E177-4158-AB7B-8749AEFA2A5AQ39693239-48BB4EEB-5489-40B3-81BC-AA988610332BQ40340521-4ADB47AF-FE77-4968-86E2-921BBD29E355Q40710199-FE277B36-E405-4F6A-BF56-8C78A9EDACEEQ40978951-82671E06-5AF2-4027-9C2B-BA5B8C22DC49Q41147831-B5F6DD9B-C193-4243-A5A8-1D091C1B8705Q41638529-9B842E44-01A4-4010-AEF4-F726E18E76AEQ41681702-CFBD8EA5-B4C8-427C-A52C-60EBB0B73E3DQ41707631-90E001C1-2C1E-44A3-B2D6-D87362E2B036Q41719608-B847B611-8341-4BA7-AB88-168513480BE8Q41727067-B6F21036-51EE-43CD-AE0E-FF14E3970E64Q41729794-31417D17-DA9B-4099-9B06-EC1554276CF7Q41812714-61259C7B-EAA9-43E0-BE37-9DF82730904EQ41876641-3A0B7286-1CE9-4CC6-AFB9-BE6E5D8C95DCQ42371753-973E8A0D-D65B-4BDC-BFF5-CBFAB2CA4B6BQ42371807-962AE40A-8A15-4248-825C-5E4848306D90Q42930123-F711FF24-D5E8-4F78-A766-C7070FC821DCQ43608675-0E668177-F6DA-4566-8D2E-36505CF36116Q43622754-D883C72F-F001-4128-8D16-68E37388AD0CQ43688392-7CF0D443-EC06-43A2-B64F-B5E5380D55D8Q43709715-018F2892-6321-45A4-99DF-035C2E499511Q43777030-28E2EFD3-96DD-44C7-8C94-085CA561EC5DQ43925182-68AACB37-0545-4840-8CD6-2014F6E75586
P2860
Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Cyclosporin A reverses vincris ...... te lymphatic leukemia in vitro
@en
type
label
Cyclosporin A reverses vincris ...... te lymphatic leukemia in vitro
@en
prefLabel
Cyclosporin A reverses vincris ...... te lymphatic leukemia in vitro
@en
P2093
P2860
P356
P1476
Cyclosporin A reverses vincris ...... te lymphatic leukemia in vitro
@en
P2093
P2860
P304
P356
10.1172/JCI112450
P407
P577
1986-04-01T00:00:00Z